Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Scheemda

6 clinical trials in Scheemda, The Netherlands. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Scheemda at a glance
6
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

6 trials in Scheemda

Open in trial search

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on Treatment-Free Intervals for Newly Diagnosed Multiple Myeloma Patients Using Daratumumab, Lenalidomide, and Dexamethasone

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Dose-Reduced Oxaliplatin and Drug Combination Study for Older Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Leiden University Medical Center

Study on Genotype-Guided Treatment with Carbasalate Calcium, Telmisartan, and Rivaroxaban for Patients with Peripheral Arterial Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carbasalate Calcium
  • Sponsor:Stichting Radboud universitair medisch centrum

Multiple sclerosis

Not recruiting

Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Natalizumab
  • Sponsor:Amsterdam UMC Stichting

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Scheemda

What the registry says about research in the country

01 Cardiovascular Research

Innovative research focusing on genotype-guided antithrombotic treatment for patients with peripheral arterial disease, aiming to reduce adverse clinical events related to arterial thrombosis.

  • Arterial Thrombosis Prevention
  • Cardiovascular Events Reduction
  • Limb Preservation Strategies

Advanced studies targeting improved outcomes in vascular health management.

02 Oncology Studies

Groundbreaking research evaluating dose-optimized chemotherapy approaches for elderly patients with metastatic colorectal cancer, alongside innovative treatment protocols for multiple myeloma.

  • Colorectal Cancer Treatment
  • Multiple Myeloma Management
  • Treatment Optimization Studies

Focused on developing personalized treatment strategies for better patient outcomes.

03 Neurology Research

Advanced studies in Multiple Sclerosis treatment optimization, investigating personalized dosing approaches with various therapeutic agents including ocrelizumab and natalizumab.

  • Personalized Treatment Protocols
  • Extended Interval Dosing
  • Disease Activity Management

Exploring innovative approaches to enhance MS treatment effectiveness and patient care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.